Lemtrada (LEM-trah-dah, alemtuzumab) will be a new IV option for relapsing-remitting forms of multiple sclerosis (MS)

Lemtrada (LEM-trah-dah, alemtuzumab) will be a new IV option for relapsing-remitting forms of multiple sclerosis (MS) in Canada.

It's for patients who don't respond adequately to interferon beta (Rebif, etc) or other disease-modifying therapies.

Lemtrada may be more effective than interferon beta.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote